Skip to main content
. 2011 Jun 17;118(12):3426–3435. doi: 10.1182/blood-2010-11-320812

Figure 2.

Figure 2

Evaluation of BMDC circulating populations after treatment with PTX or PTX in combination with either G-CSF or AMD3100. Non–tumor-bearing C57Bl/6 mice (n = 4 to 5 mice per group) were treated with PTX, PTX and G-CSF, or PTX and AMD3100. Mice were bled via retro-orbital sinus for the evaluation of (A) viable CEPs; (B) hemangiocytes; and (C) Gr-1+/CD11b+ cells (MDSCs), using flow cytometry. ***P < .001 from control group, unless indicated otherwise.